|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | |||||
| Net loss | |||||
| Net loss | |||||
| Adjustments to reconcile to net loss to net cash used in operating activities: | |||||
| Depreciation and amortization | |||||
| Debt discount amortization | |||||
| Impairment of goodwill and inventory | |||||
| Gain on disposal of fixed asset | |||||
| Imputed Interest on RP Loans | |||||
| Estimated fair value of stock based compensation | |||||
| Estimated fair value of shares issued for services | |||||
| Decrease (increase) in assets | |||||
| Prepaid expenses and deposits | |||||
| Increase (decrease) in liabilities | |||||
| Accounts Payable | |||||
| Accrued expenses | |||||
| NET CASH USED IN OPERATING ACTIVITIES | |||||
| Purchases of property and equipment | |||||
| Proceeds from disposal of fixed asset | |||||
| NET CASH PROVIDED IN INVESTING ACTIVITIES | |||||
| CASH FLOWS FROM FINANCING ACTIVITIES | |||||
| Proceeds from the sale of common stock | |||||
| Repayments on notes payable | |||||
| Increase in due to officer | |||||
| Proceeds from notes payable - related party | |||||
| Repayments on notes payable - related party | |||||
| Repayments of Notes Payable | |||||
| NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES | |||||
| NET CHANGE IN CASH | |||||
| EFFECT OF EXCHANGE RATE ON CASH | |||||
| CASH, BEGINNING OF PERIOD | |||||
| CASH, END OF PERIOD | |||||
| NET CHANGE IN CASH | |||||
| EFFECT OF EXCHANGE RATE ON CASH | |||||
| CASH, BEGINNING OF PERIOD | |||||
| CASH, END OF PERIOD | |||||
| Income taxes | |||||
| Interest paid | |||||
| Acquisition of Hemprical Genetics with common stock and note payable | |||||
Loading...
